HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ODS bibliography

This article was originally published in The Tan Sheet

Executive Summary

Fourth 1Annual Bibliography of Significant Advances in Dietary Supplement Research in 2002 is now available, Office of Dietary Supplements announces. Team of 45 nutrition, botanical sciences and public health experts selected 25 research articles published over the past year, ODS notes. Six studies each on botanicals and antioxidants were listed, including trials on antioxidant vitamin supplementation in high-risk individuals and black cohosh safety in menopausal women (2"The Tan Sheet" July 8, 2002, p. 3 and 3"The Tan Sheet" July 21, 2003, p. 4). Bibliography is designed to provide "a useful reference source for students, nutrition and health communicators, as well as scientists," ODS says...

You may also be interested in...



Black Cohosh Safety Supported By Literature Review – Menopause Study

Use of black cohosh for the treatment of menopause symptoms is safe and has a low occurrence of adverse events, according to a study published in the July issue of Menopause, the Journal of the North American Menopause Society

Antioxidant Supplementation Delayed Effects To Be Followed In UK Study

High-risk subjects in a UK intervention trial, which found no preventive effects of antioxidant vitamins against various diseases, will be monitored to determine if benefits surface after the initial study period

Biogen Sees Improving Momentum In Slow Leqembi Launch

Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS129060

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel